Key facts
- Lyric Bio’s last known valuation is $17.0M (Jul 2025).
- It has raised $6.6M; the latest was Seed Round ($6.6M) in Jul 2025.
- Notable investors include SOSV, Draper Associates, The Venture Collective, Black Diamond Ventures, Lucas Venture Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Lyric Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lyric Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lyric Bio
Operator of a biomanufacturing and therapeutics development and manufacturing firm intended to reduce Immunoglobulin therapy dependence on human donation by several orders of magnitude. The company utilizes proprietary tissue engineering technology and proprietary laser-printed cellular substrates to develop high-density tissue-mimicking bioreactors to improve access to life-saving medicines, enabling clients to expand cells from a single donor for continuous production of human immunoglobulin.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Employees
- 10
- Website
- lyricbio.com/
- Ownership
- Privately Held (backing)
Lyric Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lyric Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lyric Bio in its N-PORT filings yet. We sweep new filings monthly.